JP2022526450A5 - - Google Patents
Info
- Publication number
- JP2022526450A5 JP2022526450A5 JP2021560713A JP2021560713A JP2022526450A5 JP 2022526450 A5 JP2022526450 A5 JP 2022526450A5 JP 2021560713 A JP2021560713 A JP 2021560713A JP 2021560713 A JP2021560713 A JP 2021560713A JP 2022526450 A5 JP2022526450 A5 JP 2022526450A5
- Authority
- JP
- Japan
- Prior art keywords
- ring
- alkyl
- substituted
- independently
- heteroalkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962833473P | 2019-04-12 | 2019-04-12 | |
| US62/833,473 | 2019-04-12 | ||
| PCT/US2020/028002 WO2020210831A1 (en) | 2019-04-12 | 2020-04-13 | Inhibitors of cd40-cd154 binding |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022526450A JP2022526450A (ja) | 2022-05-24 |
| JP2022526450A5 true JP2022526450A5 (enExample) | 2023-04-20 |
Family
ID=72751487
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021560713A Pending JP2022526450A (ja) | 2019-04-12 | 2020-04-13 | Ｃｄ４０－ｃｄ１５４結合の阻害剤 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20220185785A1 (enExample) |
| EP (1) | EP3952853A4 (enExample) |
| JP (1) | JP2022526450A (enExample) |
| CN (1) | CN114173772A (enExample) |
| CA (1) | CA3136725A1 (enExample) |
| WO (1) | WO2020210831A1 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20230030056A (ko) | 2020-05-22 | 2023-03-03 | 알리고스 테라퓨틱스 인코포레이티드 | Pd-l1을 표적화하기 위한 방법 및 조성물 |
| US20250387491A1 (en) * | 2022-06-30 | 2025-12-25 | Dana-Farber Cancer Institute, Inc. | Selective histone deacetylase 8 (hdac8) degraders and methods of use thereof |
| TW202448435A (zh) * | 2023-02-28 | 2024-12-16 | 美商賽堤爾醫療公司 | 經取代之噻二唑基化合物 |
| WO2025137293A2 (en) * | 2023-12-22 | 2025-06-26 | Roche Sequencing Solutions, Inc. | Enhancement of nucleic acid polymerization by aromatic compounds |
| WO2026050121A1 (en) * | 2024-08-30 | 2026-03-05 | Roche Sequencing Solutions, Inc. | Compositions for replicating a nucleic acid template |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH07145138A (ja) * | 1993-11-24 | 1995-06-06 | Sanko Chem Co Ltd | アクリル酸誘導体 |
| CA2320416A1 (en) * | 1998-02-09 | 1999-08-12 | Fujisawa Pharmaceutical Co., Ltd. | New compound |
| GB9805866D0 (en) * | 1998-03-20 | 1998-05-13 | Zeneca Ltd | Anti-tumour agents |
| US6800651B2 (en) * | 2000-02-03 | 2004-10-05 | Eli Lilly And Company | Potentiators of glutamate receptors |
| EP1450779A1 (en) * | 2001-11-14 | 2004-09-01 | Ralph Ryback | Method for treating autoimmune diseases |
| CA2577060A1 (en) * | 2004-08-13 | 2006-02-23 | Amgen Inc. | Substituted benzofused heterocycles |
| US7674822B2 (en) * | 2004-11-24 | 2010-03-09 | Wyeth | PTP1b inhibitors |
| BRPI0815551A2 (pt) * | 2007-08-15 | 2015-02-18 | Univ South Florida | Tratamento através de hucbc de doença beta-amiloide |
| AU2009266414A1 (en) * | 2008-07-01 | 2010-01-07 | Arana Therepeutics (Vic) Pty Ltd | Anti-PAMP therapeutic antibodies |
| US20110233463A1 (en) * | 2008-09-17 | 2011-09-29 | Tetragon Lc Chemie Ag | Chiral compounds, cholesteric and ferroelectric liquid crystal compositions comprising these chiral compounds, and liquid crystal displays comprising these liquid crystal compositions |
| TWI561521B (en) * | 2011-10-14 | 2016-12-11 | Abbvie Inc | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases |
| EA201890297A1 (ru) * | 2015-07-14 | 2018-06-29 | Иммьюнекст, Инк. | Антитело к cd154, обладающее улучшенными характеристиками связывания, функциональности и безопасности, и его применение в иммунотерапии у человека |
| EP3389781B1 (en) * | 2015-12-15 | 2021-08-11 | University of Miami | Inhibitors of tnf superfamily costimulatory interactions and methods for uses of the same |
| EP3645096B1 (en) * | 2017-06-30 | 2023-06-07 | Innovgas Pty Ltd | Tapered compressible bite block |
-
2020
- 2020-04-13 CN CN202080033531.4A patent/CN114173772A/zh active Pending
- 2020-04-13 WO PCT/US2020/028002 patent/WO2020210831A1/en not_active Ceased
- 2020-04-13 US US17/603,260 patent/US20220185785A1/en not_active Abandoned
- 2020-04-13 EP EP20787970.1A patent/EP3952853A4/en not_active Withdrawn
- 2020-04-13 CA CA3136725A patent/CA3136725A1/en active Pending
- 2020-04-13 JP JP2021560713A patent/JP2022526450A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN111315737B (zh) | 经砜吡啶烷基酰胺取代的杂芳基化合物 | |
| JP5795402B2 (ja) | 新規抗血小板薬 | |
| CN114430739A (zh) | Egfr抑制剂、组合物及其制备方法 | |
| JP2010539110A5 (enExample) | ||
| JP2009517383A (ja) | 新規な３−ビシクロカルボニルアミノピリジン−２−カルボキサミド又は３−ビシクロカルボニルアミノピラジン−２−カルボキサミド | |
| JP2008517926A5 (enExample) | ||
| TW201835070A (zh) | 芳香烴受體(AhR)調節劑化合物 | |
| KR20090127307A (ko) | 히스타민 ｈ３ 수용체 조절제로서의 테트라하이드로이소퀴놀린 화합물 | |
| EA028814B1 (ru) | АМИДЗАМЕЩЕННЫЕ ГЕТЕРОЦИКЛИЧЕСКИЕ СОЕДИНЕНИЯ, ПРИМЕНИМЫЕ В КАЧЕСТВЕ МОДУЛЯТОРОВ ОТВЕТОВ, ОПОСРЕДУЕМЫХ IL-12, IL-23 И/ИЛИ IFNα | |
| JP2017508763A5 (enExample) | ||
| HK1217706A1 (zh) | 用於治疗过度增殖性病症的3-乙酰基氨基-1-(苯基-杂芳基-氨基羰基或苯基-杂芳基-羰基氨基)苯衍生物 | |
| JP2020506946A5 (enExample) | ||
| CN105008367A (zh) | 作为钾离子通道抑制剂的吡咯并三嗪类化合物 | |
| JP2017520612A (ja) | 抗がん剤としての官能化され置換されたインドール | |
| JP6592512B2 (ja) | 三環式アトロプ異性体の化合物 | |
| JP2019537603A5 (enExample) | ||
| KR102678581B1 (ko) | 바이사이클릭 코어 모이어티를 갖는 신규한 lxr 조절제 | |
| EP3752503A1 (en) | Inhibitors of trpc6 | |
| TW201623239A (zh) | 新穎２－胺基－吡啶及２－胺基－嘧啶衍生物及其醫藥用途 | |
| JP5336359B2 (ja) | テトラヒドロイソキノリン−１−オン誘導体またはその塩 | |
| TW201418233A (zh) | 新穎腎素抑制劑 | |
| WO2021175283A1 (zh) | 新型ep4拮抗剂的合成及其在癌症和炎症中的用途 | |
| JP2022526450A (ja) | Ｃｄ４０－ｃｄ１５４結合の阻害剤 | |
| JP4316232B2 (ja) | アンドロゲン受容体拮抗剤 | |
| JP2016504397A (ja) | Ｃｒａｃチャネル阻害薬としての、ピラゾリルをベースとするカルボキサミド類ｉｉ |